Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed malignant neoplasm
• * Not amenable to standard therapy or has failed existing first- and second-line therapies
• Tumor positive for somatostatin receptors by OctreoScan within the past 4 weeks
• At least 1 measurable lesion
• * Lesions that have been previously irradiated must demonstrate progression since radiation
• * At least 1 measurable somatostatin receptor-positive lesion that has not been irradiated within the past 4 weeks AND has not had full craniospinal radiation within the past 3 months
• Bone marrow with at least 40% cellularity OR at least 20% cellularity with one million CD34+ stem cells/kg stored
• No diffuse bone marrow involvement by OctreoScan scintigraphy
• PATIENT CHARACTERISTICS:
• Age
• 2 to 25
• Performance status
• COG 0-2 OR
• Karnofsky 60-100% OR
• Lansky 60-100%
• Life expectancy
• 2-12 months
• Hematopoietic
• See Disease Characteristics
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin less than 1.5 times normal
• AST and ALT less than 2.5 times upper limit of normal
• Renal
• Creatinine no greater than 1 mg/dL (children less than 5 years of age)
• Creatinine less than 1.2 mg/dL (children 5 to 10 years of age)
• Creatinine less than 1.7 mg/dL (children over 10 years of age) AND
• Glomerular filtration rate at least 80 mL/min/m\^2
• Cardiovascular
• Shortening fraction at least 28% by echocardiogram
• Ejection fraction at least 50% by bi-plane method of echocardiogram
• No prior congestive heart failure unless ejection fraction at least 40%
• No unstable angina pectoris
• No cardiac arrhythmia
• No symptomatic congestive heart failure
• Other
• No other concurrent malignancy
• No other significant uncontrolled medical, psychiatric, or surgical condition that would preclude study compliance
• No antibodies to yttrium Y 90-DOTA-tyr3-octreotide or octreotide
• No prior allergic reactions to compounds of similar chemical or biologic composition to yttrium Y 90-DOTA-tyr3-octreotide
• No ongoing or active infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 6 months after study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• Endocrine therapy
• More than 28 days since prior long-acting somatostatin analogues
• No concurrent somatostatin analogues 12 hours before or 12 hours after study drug administration
• Concurrent hormonal therapy (other than somatostatin analogue) allowed provided patient received hormonal therapy for at least 2 months and has stable disease or progressive disease
• Radiotherapy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No prior radiotherapy to 25% or more of bone marrow
• No prior external beam radiotherapy to both kidneys (scatter doses of less than 500 cGy to a single kidney or radiation to less than 50% of a single kidney is allowed)
• Surgery
• At least 4 weeks since prior surgery
• Other
• Recovered from prior therapy
• At least 4 weeks since prior investigational drugs
• No other concurrent approved or investigational anti-neoplastic therapies except for bisphosphonates
• No concurrent combination antiretroviral therapy for HIV-positive patients